The clinical efficacy, safety and usefulness of cefoselis (FK037: FK), a new parenteral cephalosporin, were evaluated in bacterial pneumonia in a comparative study versus ceftazidime (CAZ).Each drug was administered by intravenous drip infusion at a dose of 1.0g (potency), twice daily for 14 days. The following results were obtained. 1. Of the total 186 cases enrolled, 146 cases were evaluated for clinical efficacy and the efficacy rates (“good” and better responses) were 92.3% (72/78) in the FK group and 91.2% (62/68) in the CAZ group. 2. Bacteriological effects (eradication rates) were 100% (21/21) in the FK group and 96.4% (27/28) in the CAZ group. 3. Adverse reactions occurred in 3 of the 90 patients (3.3%) in the FK group and in 3 of the 88 patients (3.4%) in the CAZ group. The incidence of abnormal laboratory findings was 20.0% (18/90) in the FK group and 18.3% (15/82) in the CAZ group. The safety rate (“safe” in overall safety rating) was 78.9% (71/90) in the FK group and 81.7% (67/82) in the CAZ group. 4. Usefulness rates (“useful” and better responses) were 89.7% (70/78) in the FK group and 88.1% (59/67) in the CAZ group. No significant difference was observed between the two groups in any of the above ratings. The results indicate that FK037 is as useful as ceftazidime for the treatment of bacterial pneumonia.
ASJC Scopus subject areas
- Pharmacology (medical)